“BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA” (2016) Mediterranean Journal of Hematology and Infectious Diseases, 8, p. e2016011. doi:10.4084/mjhid.2016.011.